Press release
Orphan Drugs Market Soars Toward $435.7 Billion | Growth at 11.8% CAGR
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐ ๐จ๐ซ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ: https://www.alliedmarketresearch.com/request-sample/204
Orphan drugs are specialized pharmaceutical agents administered for the treatment of rare (orphan) diseases. These diseases have a very low prevalence rate; thus, pharmaceutical companies do not readily invest in these drugs as the returns on investment in orphan drugs are risky as compared to non-orphan drugs. Moreover, multiple clinical trials for drug testing cannot be voluntarily performed due to the small patient population. However, orphan drugs have shown tremendous potential in diagnosis and treatment of cancer; this trend is expected to continue throughout the forecast period.
๐๐๐ฒ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐๐จ๐ซ ๐๐ญ๐๐ค๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌ:
The comprehensive study provides valuable insights for stakeholders in the Orphan Drugs Market, including:
In-Depth Market Analysis: The report offers an in-depth analysis of the global orphan drugs market, unraveling current trends and future estimations to guide stakeholders towards imminent investment opportunities.
Driving and Restricting Factors: A comprehensive analysis of the factors driving and restricting the growth of the orphan drugs market is provided, offering stakeholders a nuanced understanding of market dynamics.
Quantitative Industry Analysis: The report presents a comprehensive quantitative analysis of the orphan drugs industry from 2020 to 2030, enabling stakeholders to capitalize on prevailing market opportunities.
Segmentation Insights: Extensive analysis of key segments helps stakeholders understand the applications and products of orphan drugs across the globe, offering insights into specific disease types and their prevalence.
Competitive Outlook: Key market players and their strategies have been thoroughly analyzed, providing stakeholders with a deep understanding of the competitive landscape and potential collaborations.
๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง:
By Disease Type:
Oncological Diseases
Metabolic Diseases
Hematologic & Immunologic Diseases
Infectious Diseases
Neurological Diseases
Other Rare Diseases
๐๐ฒ ๐๐๐ ๐ข๐จ๐ง:
North America (U.S, Canada, Mexico)
Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific)
LAMEA (Brazil, Turkey, South Africa, Rest of LAMEA)
๐๐๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ:
Novartis International AG (Sandoz)
Johnson & Johnson (Janssen Global Services, LLC)
Sanofi S.A
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Amryt Pharma PLC.
AbbVie Inc.
Amgen Inc.
GlaxoSmithKline PLC (GSK)
Pfizer Inc.
The Orphan Drugs Market's exponential growth underscores the importance of addressing rare diseases, offering significant opportunities for pharmaceutical companies and stakeholders to make a positive impact on global healthcare.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ : https://www.alliedmarketresearch.com/purchase-enquiry/204
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐ฌ:
David Correa
Wilmington, Delaware, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market Soars Toward $435.7 Billion | Growth at 11.8% CAGR here
News-ID: 3466031 • Views: โฆ
More Releases from Allied Market Research (AMR)
Brassylic Acid Market: Forecasted Demand and Leading Key Players Analysis
Rising demand for brassylic acid across fragrance, polymer, pharmaceutical, cosmetic, and chemical industries is significantly driving market growth. Its expanding application base, coupled with favorable material properties, is expected to fuel steady expansion of the global market throughout the forecast period.
According to a report by Allied Market Research, the global brassylic acid market was valued at $61.30 million in 2021 and is projected to reach $90.40 million by 2030, growingโฆ
EMA Rockwool Market: Opportunities, Market Share, Growth Trends, Competitive Lan โฆ
The EMA rockwool market is witnessing steady growth, driven primarily by increasing demand from the building & construction and transportation sectors. Rockwool's superior insulation properties, fire resistance, and soundproofing capabilities continue to make it a preferred material across multiple industries.
According to a report published by Allied Market Research, the EMA rockwool market was valued at $1.4 billion in 2020 and is projected to reach $2.2 billion by 2030, registering aโฆ
Phosphate Rich Organic Manure (PROM) Market Report 2026: Business Expansion, Key โฆ
The global Phosphate Rich Organic Manure (PROM) market is witnessing significant growth, driven by rising demand for organic fertilizers and increasing government initiatives promoting sustainable agriculture.
According to a recent report published by Allied Market Research, titled "Phosphate Rich Organic Manure (PROM) Market by Source: Global Opportunity Analysis and Industry Forecast, 2022-2031", the market was valued at $2.8 billion in 2021 and is projected to reach $5.7 billion by 2031, registeringโฆ
Honeycomb Paper Market - Analysis of Opportunities, Market Share, Growth Trends, โฆ
The global honeycomb paper market is witnessing steady growth, driven by the rising adoption of lightweight, sustainable core materials across multiple industries.
According to a report published by Allied Market Research, titled "Honeycomb Paper Market by Core Type, Cell Size, and End-use Industry: Global Opportunity Analysis and Industry Forecast, 2020-2030," the market was valued at $6.5 billion in 2020 and is projected to reach $11.0 billion by 2030, registering a CAGRโฆ
More Releases for Orphan
Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031.
Get Free Access toโฆ
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry โฆ
Market Overview:
According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &โฆ
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developedโฆ
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.โฆ
Europe Orphan Drugs Pipeline Analysis
โEurope Orphan Drugs Pipeline Analysisโ by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drugโฆ
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for theโฆ
